SGLT2 Inhibitors versus Sulfonylureas as Add-On Therapy to Metformin in Type 2 Diabetes: A Systematic Review and Meta-Analysis

被引：0
|
作者：
Umer, Muhammed
Salman, Ali
Nadeem, Shahrukh
Iqbal, Abiha
Tashrifwala, Fatema
Paryani, Neha Saleem
Ali, Eman
Kumar, Jai
Maniya, Muhammad Talha
Asad, Dayab
机构：
来源：
CIRCULATION | 2023年 / 148卷
关键词：
Diabetes (Type II);
D O I：
10.1161/circ.148.suppl_1.14623
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A14623
引用
收藏
页数：2
相关论文
共 50 条
  • [1] SGLT2 INHIBITORS COMPARED WITH SITAGLIPTIN AS ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Sevald, C. A.
    Jackson, J. D.
    Mcana, J. F.
    VALUE IN HEALTH, 2016, 19 (03) : A197 - A197
  • [2] Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis
    Mishriky, B. M.
    Tanenberg, R. J.
    Sewell, K. A.
    Cummings, D. M.
    DIABETES & METABOLISM, 2018, 44 (02) : 112 - 120
  • [3] The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis
    Mishriky, Basem M.
    Cummings, Doyle M.
    Tanenberg, Robert J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 109 (02) : 378 - 388
  • [4] SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF SGLT-2 INHIBITORS AND METFORMIN AS ADD-ON TO INSULIN FOR THE TREATMENT OF TYPE 1 DIABETES
    Langford, B.
    Evans, M.
    Haskins-Coulter, T.
    O'Connor, M.
    Eddowes, L. A.
    Edmonds, C.
    Tank, A.
    VALUE IN HEALTH, 2018, 21 : S121 - S121
  • [5] Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis
    Xiaoyan Zhong
    Dan Lai
    Yun Ye
    Xuping Yang
    Bin Yu
    Yilan Huang
    European Journal of Clinical Pharmacology, 2016, 72 : 655 - 663
  • [6] Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis
    Zhong, Xiaoyan
    Lai, Dan
    Ye, Yun
    Yang, Xuping
    Yu, Bin
    Huang, Yilan
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (06) : 655 - 663
  • [7] ASSOCIATION OF SGLT2 INHIBITORS WITH STROKE IN PATIENTS WITH TYPE 2 DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Mi, D.
    Pan, P.
    Chen, S.
    Chen, S.
    Peng, F.
    INTERNATIONAL JOURNAL OF STROKE, 2024, 19 (02) : 88 - 88
  • [8] Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 1 diabetes
    Zhou, Yue
    Geng, Zhuang
    Wang, Xiang
    Huang, Yajing
    Shen, Liyan
    Wang, Yangang
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2020, 36 (02)
  • [9] SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis
    Guo, Man
    Ding, Jingya
    Li, Jingsong
    Wang, Jiying
    Zhang, Ting
    Liu, Cuiping
    Huang, Wei
    Long, Yang
    Gao, Chenlin
    Xu, Yong
    DIABETES OBESITY & METABOLISM, 2018, 20 (08): : 1977 - 1982
  • [10] Effects of SGLT2 inhibitors as an add-on therapy to metformin on index of cardiac electrophysiological balance in type 2 diabetes mellitus patients
    Ziyrek, Murat
    Donmez, Esra
    Ozcan, Sevgi
    Ince, Orhan
    Sahin, Irfan
    Okuyan, Ertugrul
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2022, 26 : S100 - S100
12345